drugset / Trial / NCT01561807

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

NCT01561807 ↗

Phase 2 Completed 140 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the antiviral activity and safety of VX-787 given to healthy adult volunteers that have been inoculated with the influenza virus.

Timeline

Start
2012-03
Primary completion
2012-10
Completion
—

Outcome

Met primary endpoint

release “The study met its primary endpoint” vrtx.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimodivir Small molecule — Oral

Indications